Treatment sequencing in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) remains a major unmet clinical need ...
Led by CEO Harry Rowland, VahatiCor is developing the A-Flux coronary sinus reducer implant for coronary microvascular dysfunction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results